BioStock: Curasight gears up for phase II study in prostate cancer

Following the Curium deal this spring, Curasight has now submitted a clinical trial application and selected a CRO to carry out a phase II trial with uTRACE. The trial intends to evaluate the uTRACE for the diagnosis of prostate cancer patients. BioStock contacted Curasight CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/12/curasight-gears-up-for-phase-ii-study-in-prostate-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se